Author of the publication

Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.

, , , , , , , , and . Clin Cancer Res, 14 (20): 6590--6601 (October 2008)
DOI: 10.1158/1078-0432.CCR-07-4377

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers., , , , , , , , , and 27 other author(s). Clin Cancer Res, 21 (8): 1904-1915 (April 2015)Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes., , , , , and . BMC Cancer, (2007)Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome., , , , , , , , , and . Clin Cancer Res, 12 (17): 5118--5128 (September 2006)Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification., , , , , , , , , and 4 other author(s). J Clin Oncol, 24 (31): 5070--5078 (November 2006)Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease., , , , , , , , , and 1 other author(s). Cancer Lett, 250 (2): 250--267 (June 2007)Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR., , , , , , , , and . Clin Cancer Res, 14 (20): 6590--6601 (October 2008)Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature., , , , , , , , , and 10 other author(s). Clin Cancer Res, 16 (5): 1532--1541 (March 2010)Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients., , , , , , , , , and 2 other author(s). Clin Cancer Res, 12 (1): 131--138 (January 2006)The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models., , , , , , , , , and 193 other author(s). Nat Biotechnol, 28 (8): 827--838 (August 2010)Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas., , , , , , , , , and 4 other author(s). Genome Biol, 9 (10): R150 (2008)